Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glaxo Lotronex Withdrawal Follows Failed Risk Management Negotiations

Executive Summary

Glaxo Wellcome's withdrawal of Lotronex suggests that hurdles remain in FDA's efforts to expand the use of risk management programs for approved products.

You may also be interested in...



Pain Therapeutics Touts Naltrexone Safety Profile Over Marketed IBS Drugs

Pain Therapeutics believes its low-dose oral naltrexone will offer a more positive risk-benefit profile and broader efficacy compared to marketed irritable bowel syndrome therapies

Pain Therapeutics Touts Naltrexone Safety Profile Over Marketed IBS Drugs

Pain Therapeutics believes its low-dose oral naltrexone will offer a more positive risk-benefit profile and broader efficacy compared to marketed irritable bowel syndrome therapies

Solvay Cilansetron Irritable Bowel NDA Will Include “Appropriate Use Plan”

Solvay plans to submit a "comprehensive appropriate use plan" for cilansetron in conjunction with its upcoming NDA filing for the irritable bowel syndrome therapy

Related Content

UsernamePublicRestriction

Register

PS036975

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel